Search

Your search keyword '"Sarilumab"' showing total 784 results

Search Constraints

Start Over You searched for: Descriptor "Sarilumab" Remove constraint Descriptor: "Sarilumab"
784 results on '"Sarilumab"'

Search Results

1. Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: Post hoc analysis of a Phase III study (KAKEHASI).

2. Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: An interim analysis of a post-marketing surveillance.

3. A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis.

4. Investigating the impact of Tocilizumab, Sarilumab, and Anakinra on clinical outcomes in COVID-19: A systematic review and meta-analysis

6. Successful Salvage Therapy of Late-onset Arterial Disorders due to Recurrent Vasospasms Following Free Flap Transfer under the IL-6 and TNF-α Signaling-downregulated Environment: A Case Report

7. Risk factors for thromboembolic events in patients hospitalized for COVID-19 pneumonia in a general ward and requiring treatment with oxygen.

8. Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials.

9. Blockade of the interleukin-6 signaling pathway in rheumatoid arthritis: Effects on obesity, adipocytokines and glucose metabolism

10. Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19

11. Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis

13. Effect of Anti-Interleukin-6 Agents on Psychopathology in a Sample of Patients with Post-COVID-19 Syndrome: An Observational Study.

14. IL-6-induced response of human osteoblasts from patients with rheumatoid arthritis after inhibition of the signaling pathway.

15. COVID-19 患者使用靶向 IL-6 药物的不良事件分析 ——基于 FAERS 数据库.

16. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

17. Rheumatoid Arthritis Rheumatoid Arthritis

19. Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.

20. Léčba nemocné s aktivní revmatoidní artritidou a četnými komorbiditami: účinné a bezpečné využití sarilumabu.

21. A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages

22. Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison

23. Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: A systematic review and meta-analysis of randomized controlled trials

24. Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab.

25. Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison.

26. Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019

27. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis

28. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab

29. Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial.

30. A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages.

31. Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: Two single-dose studies.

32. Interleukin-6 and Macular Edema: A Review of Outcomes with Inhibition.

33. Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA).

34. Kdy v praxi indikovat sarilumab?

35. Is immunosuppressive therapy an effective treatment for COVID-19? – literature review

36. Effect of Anti-Interleukin-6 Agents on Psychopathology in a Sample of Patients with Post-COVID-19 Syndrome: An Observational Study

37. Sarilumab use in severe Coronavirus Disease 2019 pneumonia

38. Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19

39. Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations

40. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)Research in context

41. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.

42. Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019.

43. Rituximab, a Safer Option for Rheumatoid Arthritis: A Comparison of the Reported Adverse Events of Approved Monoclonal Antibodies.

44. Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19

45. Severe coronavirus disease 2019 in a patient with TAFRO syndrome: A case report

46. Immune-related adverse events of biological immunotherapies used in COVID-19.

47. Genomic-Analysis-Oriented Drug Repurposing in the Search for Novel Antidepressants.

48. Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study.

49. Investigating the impact of Tocilizumab, Sarilumab, and Anakinra on clinical outcomes in COVID-19: A systematic review and meta -analysis.

Catalog

Books, media, physical & digital resources